| Literature DB >> 29153836 |
Gina Lee1, Yuxiang Zheng2, Sungyun Cho3, Cholsoon Jang4, Christina England3, Jamie M Dempsey5, Yonghao Yu6, Xiaolei Liu7, Long He1, Paola M Cavaliere3, Andre Chavez3, Erik Zhang7, Meltem Isik8, Anthony Couvillon9, Noah E Dephoure3, T Keith Blackwell8, Jane J Yu7, Joshua D Rabinowitz4, Lewis C Cantley2, John Blenis10.
Abstract
mTORC1 is a signal integrator and master regulator of cellular anabolic processes linked to cell growth and survival. Here, we demonstrate that mTORC1 promotes lipid biogenesis via SRPK2, a key regulator of RNA-binding SR proteins. mTORC1-activated S6K1 phosphorylates SRPK2 at Ser494, which primes Ser497 phosphorylation by CK1. These phosphorylation events promote SRPK2 nuclear translocation and phosphorylation of SR proteins. Genome-wide transcriptome analysis reveals that lipid biosynthetic enzymes are among the downstream targets of mTORC1-SRPK2 signaling. Mechanistically, SRPK2 promotes SR protein binding to U1-70K to induce splicing of lipogenic pre-mRNAs. Inhibition of this signaling pathway leads to intron retention of lipogenic genes, which triggers nonsense-mediated mRNA decay. Genetic or pharmacological inhibition of SRPK2 blunts de novo lipid synthesis, thereby suppressing cell growth. These results thus reveal a novel role of mTORC1-SRPK2 signaling in post-transcriptional regulation of lipid metabolism and demonstrate that SRPK2 is a potential therapeutic target for mTORC1-driven metabolic disorders.Entities:
Keywords: CK1; RNA splicing; RNA stability; S6K1; SR proteins; SRPK2; cancer metabolism; de novo lipid synthesis; mTOR; nonsense-mediated decay
Mesh:
Substances:
Year: 2017 PMID: 29153836 PMCID: PMC5920692 DOI: 10.1016/j.cell.2017.10.037
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 41.582